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Abstract
Aims/hypothesis Previous studies have suggested an in-
creased risk of bladder cancer with pioglitazone exposure.
We aimed to investigate the association between pioglita-
zone exposure and bladder cancer in France.
Methods This cohort study involved use of data from the
Frenchnationalhealthinsuranceinformationsystem(Système
National d'Information Inter-régimes de l'Assurance Maladie;
SNIIRAM)linkedwiththeFrenchhospitaldischargedatabase
(Programme de Médicalisation des Systèmes d'Information;
PMSI). The cohort included patients aged 40 to 79 years who
filled a prescription for a glucose-lowering drug in 2006. The
cohort was followed for up to 42 months. Pioglitazone expo-
sure was modelled as a time-dependent variable and defined
by having filled at least two prescriptions over a 6-month
period. Incident cases of bladder cancer were identified by a
discharge diagnosis of bladder cancer combined with specific
aggressive treatment. Statistical analyses involved a multivar-
iate Cox model adjusted for age, sex and exposure to other
glucose-lowering drugs.
Results The cohort included 1,491,060 diabetic patients,
155,535 of whom were exposed to pioglitazone. We found
175 cases of bladder cancer among exposed patients and
1,841 among non-exposed patients. Incidence rates were
49.4 and 42.8 per 100,000 person-years, respectively. Pio-
glitazone exposure was significantly associated with bladder
cancer incidence (adjusted HR 1.22 [95% CI 1.05, 1.43]).
We observed a dose–effect relationship, with a significantly
increased risk for high cumulative doses (≥28,000 mg, ad-
justed HR 1.75 [95% CI 1.22, 2.50]) and long duration of
exposure (≥24 months, adjusted HR 1.36 [1.04, 1.79]).
Conclusions/interpretation In this cohort of diabetic
patients from France, pioglitazone exposure was significantly
associated with increased risk of bladder cancer.
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Abbreviations
AFSSAPS Agence Française de Sécurité Sanitaire des
Produits de Santé (French medicines agency)
COPD Chronic obstructive pulmonary disease
ICD International Classification of Diseases
KPNC Kaiser Permanente Northern California
LTD Long-term disease
PMSI Programme de Médicalisation des Systèmes
d'Information (French hospital discharge
database)
PPAR Peroxisome proliferator-activated receptor
SNIIRAM Système National d'Information Inter-régimes
de l'Assurance Maladie (French national health
insurance information system)
Introduction
Pioglitazone is an oral hypoglycaemic agent that has been
marketed in the USA since 1999 and in Europe since 2000
(France since 2002). According to the European public
assessment report for pioglitazone [1], pre-clinical studies
in rats have shown an association between pioglitazone
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DOI 10.1007/s00125-012-2538-9exposure and bladder tumours. However, pioglitazone was
not genotoxic or carcinogenic in mice, and tumours were
observed only in male rats. A possible biological asso-
ciation exists, with a potential mechanism linked to the ‘pre-
disposing’ capacity of peroxisome proliferator-activated
receptor (PPAR) and/or PPARα agonists for bladder tumours
[2, 3].
A randomised clinical trial (PROspective pioglitA-
zone Clinical Trial In macroVascular Events; the PRO-
active study) evaluated pioglitazone with a mean follow-
up of 34.5 months [4, 5]. Fourteen cases of bladder
cancer were observed in the pioglitazone group (0.5%)
vs six in the placebo group (0.2%). After a blinded
review with external experts, bladder cancer was diag-
nosed during the second year of exposure in six cases
in the pioglitazone group vs three in the placebo group
[4, 5].
A cohort study of the Kaiser Permanente Northern Cal-
ifornia (KPNC) database [6] included 193,099 patients
(30,173 patients exposed to pioglitazone and 162,926 not
exposed). The median time from first prescription for pio-
glitazone to the end of follow-up was 3.3 years. The de novo
bladder cancer incidence rate was 81.5 per 100,000 person-
years for patients exposed to pioglitazone vs 68.8 per
100,000 person-years for patients not exposed. After adjust-
ing for age, sex and use of other glucose-lowering drugs, the
association between pioglitazone use and bladder cancer
risk was not significant (HR 1.2 [95% CI 0.9, 1.5]). Another
analysis of a similar cohort found no association between
pioglitazone exposure and cancer in several other sites [7].
However, the study revealed a significantly increased risk
with exposure duration >24 months (fully adjusted HR 1.4
[95% CI 1.03, 2.0]). Long-term follow-up of this cohort is
ongoing.
On the basis of these findings, the US Food and Drug
Administration (FDA) issued a safety announcement in
2010 informing healthcare professionals and patients about
its ongoing safety review but did not conclude that pioglita-
zone increases the risk of bladder cancer [8].
On the initiative of the French medicines agency (Agence
Française de Sécurité Sanitaire des Produits de Santé; AFS-
SAPS), we conducted this study to investigate a possible
association between pioglitazone use and bladder cancer inci-
dence in a historical cohort of patients with diabetes mellitus
in France. We used a methodology similar to that used in the
KPNC study but with a much larger population. To assess the
specificity of a possible increased risk of bladder cancer
associated with pioglitazone exposure, we also investigated
the association between pioglitazone exposure and cancer in
other sites.
The results of this pioglitazone study were presented to
the AFSSAPS, which decided to suspend the use of piogli-
tazone in France in June 2011 [9].
Methods
Data source: SNIIRAM and PMSI databases The French
national health insurance system consists of several specific
schemes that cover the entire population (64.7 million
inhabitants in 2010). The general scheme covers all French
employees and represents about 75% of the population. The
national health insurance information system (Système Na-
tional d'Information Inter-régimes de l'Assurance Maladie;
SNIIRAM) contains individualised, anonymous and ex-
haustive data on all reimbursements for patient health ex-
penditure [10], including medicinal products as well as
outpatient medical and nursing care, prescribed or per-
formed by healthcare professionals. The SNIIRAM database
does not provide any direct information about the medical
indication for each reimbursement but does contain the
patient's status with respect to full reimbursement of care
related to a severe and costly long-term disease (LTD),
namely the LTD diagnosis encoded in the International Clas-
sification of Diseases, 10th edition (ICD-10; www.who.int/
classifications/icd/en/). In the general scheme of the French
national health insurance system, nearly one in seven patients
received full reimbursement for an LTD in 2008 [11].
Information from this database can be linked to the
French hospital discharge database (Programme de Médical-
isation des Systèmes d'Information; PMSI), which provides
medical information about all patients admitted to hospital
in France, including discharge diagnoses encoded according
to ICD-10, medical procedures and French diagnosis-related
groups [12].
Approval from the French data protection agency
(Commission Nationale de l'Informatique et des Libertés;
CNIL) was obtained to conduct the present study.
Study population and follow-up All patients aged 40 to
79 years on 31 December 2006 and registered in the French
national health insurance general scheme were eligible for
inclusion. Included patients had to have filled at least one
prescription for a glucose-lowering drug (metformin, sulfo-
nylurea, pioglitazone, rosiglitazone,other oralhypoglycaemic
agent and/orinsulin)in 2006. The dateof the first prescription
ofa glucose-loweringdrugin2006constituted thestudy entry
date.
Patients were excluded if they had bladder cancer diag-
nosed before study entry or within the first 6 months after
study entry (screening for all PMSI discharge diagnoses
since 2005 and all SNIIRAM LTDs since 1987). Patients
with bladder cancer as a recognised occupational disease
according to SNIIRAM were also excluded.
Follow-up started 6 months after study entry to allow for
sufficient time to observe drug exposure. Follow-up ended
at the time of the earliest of the following events: more than
4 consecutive months without having filled any drug
1954 Diabetologia (2012) 55:1953–1962prescription, diagnosis of bladder cancer, death from any
cause or end of the observation period on 31 December
2009.
Definition of exposure Exposure to pioglitazone was deter-
mined from study entry onward and was defined as filling at
least two prescriptions for pioglitazone over 6 consecutive
months. Exposure was modelled as a time-dependent vari-
able as follows: patients were considered not to be exposed
from the time of study entry until the third month after
meeting the above exposure conditions and exposed from
the following month until the end of follow-up, even if the
patient discontinued treatment. The same rule was applied
with the other groups of glucose-lowering drugs.
The cumulative dose of pioglitazone was measured by
determining the total dose dispensed since study entry. The
cumulative dose was also considered to be a time-dependent
variable by evenly distributing the total dose of each pre-
scription over all days between the date of the prescription
and the date of the subsequent prescription; the dose dis-
pensed for the last prescription was not considered. The
cumulative duration of pioglitazone use was calculated in
the same way, counting 1 day for one pioglitazone tablet and
1 day for two tablets combining pioglitazone and metfor-
min. Therefore, gaps in treatment did not contribute to
cumulative duration. Cumulative doses and durations were
classified according to the same intervals used in the KPNC
study [6].
Outcome The main outcome was the incidence of bladder
cancer during the follow-up period. Bladder cancer cases
were identified by a hospital discharge diagnosis (ICD-10
code C67) and a specific surgical procedure (total cystec-
tomy by laparotomy, or partial cystectomy by laparotomy or
laparoscopy) and/or intravesical instillation of a pharmaco-
logical product by urethral catheter and/or chemotherapy
and/or radiation therapy performed during the same hospital
stay.
A broader definition of bladder cancer was used in an
additional analysis, requiring only the presence of a dis-
charge diagnosis of bladder cancer, including, in particular,
endoscopic tumour resections for bladder cancer. The
broader definition was also used to determine incidence
rates of cancer in five other sites: lung (ICD-10 codes C33
and C34), head and neck (C00 to C14), colorectum (C18 to
C21), female breast (C50) and kidney (C64).
Confounding factors The following potential confounding
factors were available from the databases: age, sex and use
of other glucose-lowering drugs.
Because the databases did not provide data on the dura-
tion of diabetes, the duration of full reimbursement for
diabetes was used as a proxy for disease duration (in the
subgroup of patients entitled to full reimbursement for dia-
betes treatment).
Data on smoking status were also absent from the data-
bases. Therefore, we calculated two variables: (1) the use of
drugs specific for chronic obstructive pulmonary disease
(COPD; defined by having filled prescriptions for tio-
tropium bromide on at least three different dates in 2006);
and (2) the presence of a hospital discharge diagnosis related
to tobacco use in 2006 (ICD-10 codes F17, Z71.6 and
Z72.0). Because only a small proportion of tobacco users
could be identified by these two variables, we did not use
this factor for model adjustment but only to compare
pioglitazone-exposed to non-exposed patients.
Statistical analysis We compared categorical and continuous
variables between pioglitazone-exposed and non-exposed
patients using the χ
2 test and Wilcoxon test, respectively,
a n du s e dt h eM a n t e l –Haenszel method for age and sex-
adjusted comparisons ofvariables related totobacco smoking.
We calculated crude incidence rates of bladder cancer for
pioglitazone-exposed and non-exposed patients by dividing
the respective number of cases by the overall follow-up
attributed to exposure and non-exposure, respectively (i.e.
follow-up before the start of exposure was considered
non-exposure).
We estimated the adjusted HRfor bladder cancerincidence
with pioglitazone exposure using a Cox proportional hazard
model with the covariates age at study entry (in 5-year inter-
vals), sex and use of other glucose-lowering drugs. The ad-
justed HRs for increasing cumulative dose and duration with
exposure compared with non-exposure were estimated in the
sameway. The timescale ofthe model was durationoffollow-
up measured in calendar months.
To assess the sensitivity of the estimated HR with respect
to several possible models, we performed the following
additional analyses:
1. Use of age as the timescale (in calendar months) as an
alternative approach to adjust for age;
2. Exclusion of patients with a pioglitazone prescription in
the first 6 months of 2006 (followed by another pre-
scription within 6 months);
3. In the subgroup of patients with full reimbursement for
diabetes treatment for at least 1 year at study entry, an
additional adjustment for duration of full reimbursement
(in intervals of 1–4, 5–9, 10–14 and ≥15 years);
4. Use of the broader definition of bladder cancer, based
simply on hospital discharge diagnoses without the ad-
ditional requirement for treatment information used to
define the primary outcome.
Further analyses addressed the question of whether a
possible increased risk of bladder cancer with pioglita-
zone exposure was specific to pioglitazone:
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glucose-lowering drug, namely metformin;
6. Analysis of risk of cancer in five other sites (identified
by hospital discharge diagnoses).
All analyses involved the use of SAS statistical soft-
ware,version 9.1 (SAS Institute,Cary, NC, USA). p<0.05
was considered statistically significant.
Results
Description of the cohort population The study included
1,491,060 diabetic patients, 155,535 (10.4%) of whom
were exposed to pioglitazone during the study period.
Figure 1 shows a flow chart describing the study
population.
The proportion of men was similar between pioglitazone-
exposedandnon-exposedpatients:53.8%vs53.4%(Table1).
The mean age was lower for pioglitazone-exposed than non-
exposed patients: 61.5 vs 63.4 years. Patients <70 years old
represented 75.6% of exposed patients vs 67.1% of non-
exposed patients. Compared with non-exposed patients,
pioglitazone-exposed patients were more frequently exposed
to metformin (82.7% vs 68.2%) and sulfonylureas (72.2% vs
55.5%) but less frequently to insulin (19.2% vs 27.6%). The
proportion of patients with specific treatment for COPD was
0.89% for pioglitazone-exposed patients vs 1.11% for non-
exposed patients. In addition, fewer pioglitazone-exposed
than non-exposed patients had a discharge diagnosis related
to tobacco smoking: 1.09% vs 1.41%, respectively. These
differences were statistically significant, even after adjusting
for age and sex.
A total of 782,675 (52.5%) patients had received full
reimbursement for diabetes treatment for at least 1 year.
Within this patient subgroup, the duration of full reimburse-
ment was shorter for pioglitazone-exposed than non-
exposed patients (mean duration 6.5 vs 7.8 years). Patients
who had received full reimbursement for at least 15 years
represented 8.5% and 15.9% of patients in each group,
respectively.
In the overall study population, the mean duration of
follow-up (starting 6 months after study entry) was
37.5 months. For pioglitazone-exposed patients, the mean
follow-up was 39.9 months, with 27.4 months attributed to
exposure. The mean interval between the last and first
pioglitazone prescription (from study entry onward) was
22.2 months. Among all pioglitazone-exposed patients,
38,925 (25.0%) filled a prescription for pioglitazone in
January 2006 and 59,296 (38.1%) during the first 6 months
of 2006.
Association of pioglitazone exposure and bladder cancer We
identified 175 incident bladder cancers among pioglitazone-
exposed patients compared with 1,841 incident bladder can-
cers among non-exposed patients. Crude incidence rates
were 49.4 and 42.8 per 100,000 person-years, respectively.
After adjusting for age, sex and use of other glucose-
lowering drugs, pioglitazone exposure was significantly
associated with incident bladder cancer (HR 1.22 [95% CI
1.05, 1.43]) (Table 2). There was no evidence of an associ-
ation between exposure to other glucose-lowering drugs and
incidence of bladder cancer. Analysis by sex revealed a
significant association between pioglitazone and bladder
cancer for men (adjusted HR 1.28 [95% CI 1.09, 1.51])
but not women (adjusted HR 0.78 [95% CI 0.44, 1.37]);
we found only 13 cases of bladder cancer among
pioglitazone-exposed women, compared with 213 cases
among non-exposed women.
We observed a dose–effect relationship, with a significant
increase in risk for cumulative duration of exposure 12 to
23 months (adjusted HR 1.34 [95% CI 1.02, 1.75]) and
≥24months(adjustedHR1.36[95%CI1.04,1.79])(Table3).
The riskwas increased 75% for cumulativedoses ≥28,000mg
(adjusted HR 1.75 [95% CI 1.22, 2.50]). Somewhat
larger estimates were observed for men for durations
≥24 months (adjusted HR 1.44 [95% CI 1.09, 1.91]) and
cumulative doses ≥28,000 mg (adjusted HR 1.88 [95% CI
1.30, 2.71]).
The results from the additional analyses were as follows:
1. When age was used as the time scale, the adjusted HR
was 1.28 (95% CI 1.10, 1.50);
2. After excluding patients with a pioglitazone prescription
in the first 6 months of 2006, the adjusted HR was 1.17
(95% CI 0.94, 1.47, p00.17) and the adjusted HR for
Patients with bladder cancer 
before the start of follow-up  
n=8,273 
Patients who left the study 
before the start of follow-up
(6 months after study entry) 
owing to death and/or 4-month 
gap in drug reimbursement 
n=72,741 
Patients with bladder cancer as 
recognised occupational 
disease  
n=28
Total population included in the cohort 
n=1,491,060
Patients under 40 years or 
over 79 years of age on 
31 December 2006  
n=349,803
Patients from the French national health 
insurance general scheme (N=48,400,000) 
who filled a prescription for a glucose-
lowering drug in 2006 
n=1,921,905
Fig. 1 Flow chart of the pioglitazone and risk of bladder cancer study
population
1956 Diabetologia (2012) 55:1953–1962doses ≥28,000 mg was 1.94 (95% CI 0.73, 5.19, p0
0.19);
3. With an additional adjustment for duration of full reim-
bursement for diabetes treatment in the patient subgroup
concerned, the adjusted HR was 1.20 (95% CI 0.98,
1.48). The duration of full reimbursement was not sig-
nificantly associated with bladder cancer incidence:
compared with a duration of 1–4 years, for 5–9 years,
the adjusted HR was 0.98 (95% CI 0.84, 1.13); for 10–
14 years, adjusted HR 0.94 (95% CI 0.78, 1.13); and for
≥15 years, adjusted HR 0.98 (95% CI 0.81, 1.18);
4. Analysis using the broader definition of bladder cancer
also revealed an association with pioglitazone exposure
(adjusted HR 1.13 [95% CI 1.03, 1.25]) and a dose–
effect relationship for exposure duration ≥24 months
(adjusted HR 1.23 [95% CI 1.03, 1.47]) and cumu-
lativedoses≥28,000mg(adjustedHR1.44[95%CI1.13,
1.84]);
5. After excluding pioglitazone-exposed patients, we ob-
served no dose–effect relationship between metformin
use and bladder cancer: compared with non-exposure,
the adjusted HRs for the dose quintiles (interval limits
870, 1,740, 2,461, and 3,185 g) were 1.00 (95% CI
0.88, 1.15), 1.14 (95% CI 1.00, 1.29), 1.05 (95% CI
0.90, 1.24), 1.07 (95% CI 0.87, 1.32) and 1.11 (95% CI
0.83, 1.49), respectively;
6. We observed no significant association between piogli-
tazone exposure and incidence of lung cancer, colorectal
cancer, breast cancer in women, or kidney cancer
(Table 4). For head and neck cancer, the adjusted HR was
0.85 [95% CI 0.73, 0.99]; p00.041.
Discussion
We conducted this cohort study at the request of the AFS-
SAPS in response to a pharmacovigilance signal and the
results of a US epidemiological study based on the KPNC
database [6], suggesting a possible relationship between
prolonged exposure (>2 years) to pioglitazone and increased
risk of bladder cancer. Analysis of this cohort of 1.5 million
diabetic patients, followed between 2006 and 2009, with
Table 1 Demographics and
glucose-lowering drug use by
pioglitazone exposure: French
cohort of diabetic patients aged
40–79 years (followed between
2006 and 2009)
Data are obtained from the
SNIIRAM and PMSI databases
p<0.01 for all comparisons
N/A, not applicable; OHA, oral
hypoglycaemic agent
Characteristic Overall study population Not exposed to pioglitazone Exposed to pioglitazone
n (%) n (%)
N 1,491,060 1,335,525 155,535
Men 796,586 712,831 (53.4) 83,755 (53.8)
Age (years)
40–44 55,903 49,789 (3.7) 6,114 (3.9)
45–49 94,472 82,593 (6.2) 11,879 (7.6)
50–54 158,419 137,813 (10.3) 20,606 (13.2)
55–59 237,091 207,912 (15.6) 29,179 (18.8)
60–64 237,327 210,837 (15.8) 26,490 (17.0)
65–69 230,578 207,344 (15.5) 23,234 (14.9)
70–74 254,631 232,172 (17.4) 22,459 (14.4)
75–79 222,639 207,065 (15.5) 15,574 (10.0)
Exposure to other glucose-lowering drugs
Rosiglitazone 153,334 126,876 (9.5) 26,458 (17.0)
Metformin 1,039,844 911,143 (68.2) 128,701 (82.7)
Sulfonylurea 853,605 741,380 (55.5) 112,225 (72.2)
Other OHA 440,633 371,447 (27.8) 69,186 (44.5)
Insulin 398,835 368,913 (27.6) 29,922 (19.2)
Pioglitazone use during follow-up
Cumulative dose (mg)
<10,500 66,332 N/A 66,332 (42.6)
10,500–27,999 54,956 N/A 54,956 (35.3)
≥28,000 34,247 N/A 34,247 (22.0)
Duration of exposure (days)
<360 58,756 N/A 58,756 (37.8)
360–719 36,482 N/A 36,482 (23.5)
≥720 60,297 N/A 60,297 (38.8)
Diabetologia (2012) 55:1953–1962 1957median duration of pioglitazone exposure 1.5 years, showed
that pioglitazone exposure was significantly associated with
increased risk of bladder cancer (adjusted HR 1.22 [95% CI
1.05, 1.43]). Higher HRs were observed for high cumulative
doses of pioglitazone (≥28,000 mg, adjusted HR 1.75 [95%
CI 1.22, 2.50]) and long duration of exposure (≥24 months,
Table 2 Risk of bladder cancer with pioglitazone exposure: French cohort of diabetic patients aged 40–79 years (followed between 2006 and 2009)
Characteristic Overall study population Men Women
(N01,491,060; 2,016 cases) (n0796,586; 1,790 cases) (n0694,474; 226 cases)
HR
a (95% CI) p value HR
a (95% CI) p value HR
a (95% CI) p value
Sex, reference women
Men 7.65 (6.66, 8.79) <0.01 N/A N/A
Age (years), reference 40–44
45–49 2.51 (0.85, 7.41) 0.10 2.39 (0.68, 8.40) 0.17 2.98 (0.35, 25.49) 0.32
50–54 5.70 (2.08, 15.60) <0.01 6.64 (2.09, 21.13) <0.01 2.90 (0.36, 23.15) 0.32
55–59 7.89 (2.93, 21.28) <0.01 9.65 (3.08, 30.25) <0.01 2.30 (0.29, 18.11) 0.43
60–64 15.34 (5.72, 41.13) <0.01 18.82 (6.04, 58.67) <0.01 4.31 (0.57, 32.37) 0.16
65–69 20.61 (7.70, 55.19) <0.01 24.57 (7.89, 76.50) <0.01 8.69 (1.19, 63.35) 0.03
70–74 30.37 (11.36, 81.17) <0.01 35.54 (11.43, 110.49) <0.01 14.74 (2.05, 105.93) 0.01
75–79 35.08 (13.12, 93.80) <0.01 41.32 (13.28, 128.53) <0.01 16.02 (2.23, 115.14) 0.01
Exposure to glucose-lowering drugs
b
Pioglitazone 1.22 (1.05, 1.43) 0.01 1.28 (1.09, 1.51) <0.01 0.78 (0.44, 1.37) 0.39
Rosiglitazone 1.08 (0.92, 1.26) 0.35 1.10 (0.93, 1.30) 0.25 0.89 (0.53, 1.49) 0.66
Metformin 1.03 (0.93, 1.13) 0.60 1.03 (0.93, 1.14) 0.58 0.99 (0.75, 1.31) 0.96
Sulfonylurea 0.92 (0.84, 1.01) 0.08 0.91 (0.83, 1.01) 0.06 0.99 (0.76, 1.30) 0.95
Other OHA 1.00 (0.90, 1.11) 0.93 0.95 (0.85, 1.07) 0.40 1.36 (1.02, 1.81) 0.04
Insulin 1.08 (0.97, 1.21) 0.15 1.08 (0.96, 1.21) 0.20 1.10 (0.81, 1.50) 0.53
Data are from SNIIRAM and PMSI databases
aAdjusted HRs estimated from multivariate Cox model including age, sex (when applicable) and exposure to glucose-lowering drugs
bFor each class of glucose-lowering drug, non-exposure was the reference group for calculation of the HR associated with exposure
N/A, not applicable; OHA, oral hypoglycaemic agent
Table 3 Risk of bladder cancer with increasing level of pioglitazone use during follow-up: French cohort of diabetic patients aged 40–79 years
(followed between 2006 and 2009)
Exposure Overall study population Men Women
HR
a (95% CI) p value HR
a (95% CI) p value HR
a (95% CI) p value
Cumulative dose (mg)
b
<10,500 1.12 (0.89, 1.40) 0.34 1.17 (0.92, 1.48) 0.21 0.77 (0.36, 1.65) 0.51
10,500–27,999 1.20 (0.93, 1.53) 0.16 1.24 (0.96, 1.60) 0.10 0.84 (0.35, 2.06) 0.71
≥28,000 1.75 (1.22, 2.50) <0.01 1.88 (1.30, 2.71) <0.01 0.57 (0.08, 4.11) 0.58
Duration of exposure (days)
b
<360 1.05 (0.82, 1.36) 0.68 1.10 (0.84, 1.43) 0.49 0.76 (0.34, 1.72) 0.51
360–719 1.34 (1.02, 1.75) 0.03 1.39 (1.06, 1.84) 0.02 0.87 (0.32, 2.35) 0.79
≥720 1.36 (1.04, 1.79) 0.02 1.44 (1.09, 1.91) 0.01 0.71 (0.22, 2.23) 0.56
Data are from SNIIRAM and PMSI databases
aAdjusted HRs estimated from multivariate Cox model including age, sex (when applicable), level of pioglitazone use (i.e. cumulative dose and
duration of exposure, respectively) and exposure to other glucose-lowering drugs
bNon-exposure was the reference group for calculating the HR associated with increasing level of pioglitazone use
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Diabetologia (2012) 55:1953–1962 1959adjusted HR 1.36 [95% CI 1.04, 1.79]). Sensitivity analyses
of various models showed the robustness of the results.
These results confirm those of the KPNC study [6], based
on 193,099 patients, including 30,173 exposed to pioglita-
zone with a median duration of exposure of 2.0 years:
adjusted HR 1.2 [95% CI 0.9, 1.5]. The KPNC study
revealed a comparable dose–effect relationship for exposure
duration ≥24 months: adjusted HR 1.4 [95% CI 1.03, 2.0].
The similarity of the results between these two studies,
conducted in different countries with distinct health systems
and data-collection procedures, is striking and provides
support for a causal association. In July 2011, the European
Medicines Agency Committee for Medicinal Products for
Human Use (CHMP) reported the results of a meta-analysis
of randomised controlled clinical studies: 19 of 12,506
patients receiving pioglitazone had bladder cancer (0.15%)
as compared with 7 of 10,212 patients not receiving pioglita-
zone (0.07%) [13].
One of the strengths of our study is that it used two
comprehensive databases that were independent in terms
of data collection. Data for medicinal product reimburse-
ment are regularly and exhaustively submitted by all French
pharmacists to the national health insurance network by
electronic data interchange, and all French hospitals regu-
larly submit their discharge data to the agency for informa-
tion on hospital care (Agence Technique de l'Information
sur l'Hospitalisation; ATIH) for planning and funding pur-
poses. The a posteriori linkage between these two databases
should have prevented observation bias, because identifica-
tion of bladder cancer incidence is completely independent
of measurement of pioglitazone exposure, in that this drug is
mainly prescribed out of hospital.
Another strong point of the study is the systematic avail-
ability of data for all drugs eligible for reimbursement. The
data on glucose-lowering drug use should therefore be com-
prehensive, because no self-prescribed medication for dia-
betes has marketing authorisation, and all glucose-lowering
products are reimbursed by the national health insurance.
We minimised the misclassification of non-exposed
patients as exposed patients by requiring exposed patients
to meet the criterion of two pioglitazone prescriptions filled
over a 6-month period. Patients who filled only one piogli-
tazone prescription (n015,756) were not classified as ex-
posed. Some of these patients may have stopped treatment
(e.g. because of an early adverse event) or never used the
dispensed medication (e.g. because of a change in the initial
treatment plan). Patients who received several pioglitazone
prescriptions but never within a single 6-month period (n0
4,746) were also not classified as exposed. Some of these
patients may have been actually exposed to pioglitazone.
However, this classification error is unlikely to be substan-
tial in view of the low use level, which is unlikely to modify
the cancer risk. Furthermore, because these individuals
represent a small proportion (3.1%) of those who met the
exposure conditions and a very small proportion (0.4%) of
the population classified as non-exposed, the potential impact
on the estimate of the association is limited.
Two other elements support the specificity of the associ-
ation of pioglitazone and bladder cancer: first, we found that
use of none of the other oral hypoglycaemic treatments was
associated with increased risk of bladder cancer, and second,
pioglitazone exposure was not associated with increased
risk of cancer in other sites. Insulin use appeared to be
linked to increased cancer risk for all cancer sites studied
(except for female breast cancer). This observation has been
previously reported [14–17]. However, because our study
was specifically designed to measure the risk of bladder
cancer directly related to pioglitazone exposure, the results
concerning use of other glucose-lowering therapies (oral or
insulin) or other cancer sites should be interpreted with
caution.
We observed a significant risk excess of bladder cancer in
men only. Previous research has suggested that this effect in
male rats can be prevented with dietary modification, sug-
gesting a mechanism related to the acid milieu and urine
bladder anatomy of male rats [18]. However, we believe that
the power of our study is far too low to be sufficient to
detect a risk for bladder cancer in women, with only 13
cases in exposed women vs 162 cases observed in exposed
men.
Our study has several limitations. First of all, it lacks data
on tobacco use, known to be the third main risk factor for
bladder cancer after age and male sex [19, 20]. Neverthe-
less, several elements seem to address this limitation. First,
the results reported by Lewis et al [6] for KPNC were
similar after adjusting for age, sex and additional covariates,
particularly smoking. Second, patients using specific drugs
for COPD and with a discharge diagnosis related to tobacco
were relatively few in the pioglitazone-exposed group,
which suggests a lower proportion of tobacco use in ex-
posed patients. Finally, the low risk of lung cancer and head
and neck cancer with pioglitazone exposure also suggests a
lower exposure to tobacco among pioglitazone users than
among non-users. Therefore, the lack of adjustment for
smoking would be expected to result, if anything, in an
underestimate of the association between pioglitazone ex-
posure and bladder cancer.
In addition, we do not report data on the duration of
diabetes. In an additional analysis of patients entitled to full
reimbursementfor diabetestreatment,weuseddurationoffull
reimbursement as a proxy. Additional adjustment for this
variable resulted in a similar HR for pioglitazone exposure
and the duration of full reimbursement for diabetes treatment
was not significantly associated with bladder cancer.
Although our report does not contain information on
histological diagnosis, the definition of bladder cancer
1960 Diabetologia (2012) 55:1953–1962patients as those requiring relatively aggressive treatment
should have minimised misclassification of non-cases as
cases. However, bladder cancer patients not treated aggres-
sively would have been missed. The incidence rates of
bladder cancer we observed were similar to those reported
by French cancer registries [21] up to the age of 80 years,
for both men and women. However, several studies of
diabetic populations have reported a slight increase in can-
cer risk in general [17] and bladder cancer risk in particular.
The meta-analysis by Larsson et al reported an increased
risk of bladder cancer (relative risk 1.24 [95% CI 1.08,
1.42]) when comparing type 2 diabetic individuals with
non-diabetic individuals [22]. French cancer registries are
population-based and these findings suggest a slight under-
estimation of the number of bladder cancer cases in our
study. However, with our data-collection method (hospital
discharge diagnoses and specific therapy), this underestima-
tion concerns both pioglitazone-exposed and non-exposed
patients. This non-differential misclassification of disease
would be expected to result in an underestimate of the risk
associated with exposure to pioglitazone. Furthermore, our
analysis using a broader definition of bladder cancer, testing
only hospital discharge diagnoses, also indicates a signifi-
cant association between pioglitazone exposure and bladder
cancer risk.
We observed a dose–effect relationship for pioglitazone
exposure only. If the increased incidence of bladder cancer
was due to deterioration of diabetes and not directly linked
to pioglitazone use, we would expect a similar increased risk
with the highest doses of metformin. Our findings, therefore,
support the theory that the increased bladder cancer risk
among patients exposed to pioglitazone cannot be explained
by disease progression.
Information on drug exposure before 2006 was not avail-
able. About one-third ofpioglitazone-exposed patientsfilleda
prescriptionforpioglitazoneduringthefirst3monthsof2006,
but pioglitazone use in France was less frequent before than
after 2005 (the number of packages reimbursed in 2004 rep-
resented approximately 20% of those reimbursed in 2006).
Pre-study exposure to pioglitazone would therefore have
concerned a maximum of one-third of exposed patients and
the duration of pre-study exposure would rarely have
exceeded1year.Moreover,theHRestimatesofouradditional
analysisinnewusersofpioglitazonewereinlinewiththoseof
themainanalysis,buttheconfidenceintervalswerebroaderas
a result of the smaller number of patients.
The French SNIIRAM and PMSI databases have been
extensively used in pharmacoepidemiological studies. A
search on 1 June 2009 for published studies involving drug
reimbursement data from SNIIRAM found 110 articles [23].
The combined use of SNIIRAM and PMSI databases in
observational pharmacoepidemiological studies is a promis-
ing approach to assess the potential for use of a drug to
produce serious adverse reactions leading to hospital
admission.
In summary, in this cohort of 1.5 million diabetic patients
followed between 2006 and 2009, pioglitazone exposure
was significantly associated with increased risk of bladder
cancer. Risk estimates were similar to those observed in the
KPNC cohort [6] but in a much larger population and in
France. Despite its limitations, this study, using linked data
from the SNIIRAM health insurance information system
and the PMSI database in France, demonstrated that these
medico-administrative databases can be helpful in address-
ing a large number of public health issues such as estimation
of disease frequencies and related healthcare spending, as
well as assessment of drug safety.
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